Tracleer (Bosentan) has been approved by the FDA to treat a rare but fatal lung disorder called pulmonary arterial hypertension, and is currently in clinical trials to gain approval for treatment of primary pulmonary hypertension (PPH).
Primary pulmonary hypertension is an extremely complex lung condition with no known cure. A progressive disease affecting about 100,000 people worldwide, PPH may lead to congestive heart failure and respiratory failure. PPH is most common in women between ages 21 and 40. Doctors are not sure what causes the illness but it has been linked to the recalled appetite suppressant known as Fen-Phen .
Read More about PPH and Diet Drugs
Tracleer is an alternative therapy to the more invasive prostacyclin agents Flolan and Remodulin. This drug is taken orally and is the first oral PPH therapy to get full FDA approval in the US. In tests and clinical trials the drug proved its effectiveness by improving arterial capacity and reducing pressure in the blood vessels of the lungs.
If you or someone you love has been diagnosed with PPH, you may be entitled to compensation.
Home / PPH and Diet Drugs / Tracleer Treatment / Other PPH Treatments / Your Legal Rights / Hire a PPH Attorney / News / Refer This Site
